UNIVERSITY OF WASHINGTON
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Glenohumeral Cortisone Injection
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 9
- Registration Number
- NCT04216017
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Acupuncture for Headache Post-Traumatic Brain Injury: A Feasibility Study
Not Applicable
Terminated
- Conditions
- Post-Traumatic HeadacheTraumatic Brain Injury
- Interventions
- Other: Acupuncture
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2
- Registration Number
- NCT04216173
- Locations
- 🇺🇸
Harborview Injury Prevention and Research Center, Seattle, Washington, United States
Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences
Not Applicable
- Conditions
- Alcohol; Use, Problem
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 408
- Registration Number
- NCT04213846
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Phase 2
Active, not recruiting
- Conditions
- Recurrent Chronic Lymphocytic LeukemiaRecurrent Grade 1 Follicular LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Plasma Cell MyelomaRecurrent Grade 3 Follicular LymphomaRecurrent Grade 3a Follicular Lymphoma
- Interventions
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT04205409
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Use of Virtual Reality for Pelvic External Fixator Removal
Not Applicable
- Conditions
- Pelvic Fracture Pubic Rami Multiple - Unstable Closed
- Interventions
- Other: Virtual Reality
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT04202315
- Locations
- 🇺🇸
University of Washington/Harborview Medical Center, Seattle, Washington, United States
Iterative Redesign of a Behavioral Skills Training Program for Use in Educational Settings
Completed
- Conditions
- Autism Spectrum DisorderDisruptive Behavior
- Interventions
- Behavioral: RUBIESBehavioral: RUBI
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT04199533
- Locations
- 🇺🇸
Seattle Public Schools, Seattle, Washington, United States
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
Phase 1
Terminated
- Conditions
- Refractory Acute Myeloid LeukemiaMyeloid NeoplasmRecurrent Acute Myeloid Leukemia
- Interventions
- Drug: CladribineDrug: CytarabineBiological: Recombinant Granulocyte Colony-Stimulating FactorDrug: Mitoxantrone
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 13
- Registration Number
- NCT04196010
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Addressing Microaggressions in Racially Charged Patient-provider Interactions: A Pilot Randomized Trial
Not Applicable
Completed
- Conditions
- Racism
- Interventions
- Other: Bias-reduction Intervention
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 25
- Registration Number
- NCT04180956
- Locations
- 🇺🇸
Bastyr University Seattle Clinic, Seattle, Washington, United States
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Phase 2
Recruiting
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Procedure: Positron Emission TomographyProcedure: LymphadenectomyDrug: Abiraterone AcetateProcedure: Computed TomographyRadiation: Radiation TherapyProcedure: PSMA PET ScanDrug: PrednisoneDrug: Abiraterone
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT04175431
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
Phase 1
Terminated
- Conditions
- Recurrent Follicular LymphomaGrade 3b Follicular LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaNon-Hodgkin's Lymphoma
- Interventions
- Drug: CopanlisibDrug: GemcitabineDrug: CarboplatinDrug: DexamethasoneBiological: RituximabBiological: Pegfilgrastim
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT04156828
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath